Related Experiment Videos

[Clinical evaluation of imipenem/cilastatin sodium in the pediatric field]

Insights

Imipenem/cilastatin sodium demonstrated 100% clinical efficacy in pediatric infections. This antibiotic showed a favorable safety profile, with only minor, transient side effects in one patient, suggesting it is a safe and effective treatment option.

Area of Science:

  • Infectious Diseases
  • Pediatric Medicine
  • Pharmacology

Background:

  • Pediatric infections require effective and safe antimicrobial agents.
  • Carbapenem antibiotics offer broad-spectrum activity.
  • Imipenem/cilastatin sodium is a combination antibiotic with established efficacy.

Purpose of the Study:

  • To evaluate the safety and efficacy of imipenem/cilastatin sodium (MK-0787/MK-0791) in pediatric patients.
  • To assess the clinical outcomes and adverse events associated with this antibiotic in a pediatric population.

Main Methods:

  • A clinical study involving 7 pediatric patients with infections.
  • Administration of imipenem/cilastatin sodium (MK-0787/MK-0791).
  • Monitoring for clinical efficacy and adverse events.

Main Results:

  • Achieved a 100% clinical efficacy ratio in the treated pediatric patients.
  • Observed a favorable safety profile with no significant side effects.
  • Transient elevations in S-GOT, S-GPT, and eosinophilia were noted in only one patient.

Conclusions:

  • Imipenem/cilastatin sodium (MK-0787/MK-0791) is a safe and effective antibiotic for treating pediatric infections.
  • The antibiotic demonstrated excellent clinical outcomes with minimal adverse events.
  • Further investigation may support its broader use in pediatric infectious disease management.

Related Concept Videos